Is Tumour Vaccination a Valid Alternative to Second Line Treatment in Hormone Refractory Prostate Cancer?--A Review of the Evidence

Author： Debacker T.   Michielsen D.   Keuppens F.  

Publisher： Ashgate Publishing Ltd

ISSN： 1561-0950

Source： UroOncology, Vol.3, Iss.1, 2003-01, pp. : 1-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Battle Against Hormone-Refractory Prostate Cancer: Is Satraplatin the Second-Line Savior?

By Adis International Limited  

Pharmaceutical & Diagnostic Innovation, Vol. 4, Iss. 5, 2006-01 ,pp. : 7-9

Adis International

Access to resources Recommend Favorite

Treatment Options in Hormone-Refractory Prostate Cancer: Current and Future Approaches

By Harris K.A.   Reese D.M.  

Drugs, Vol. 61, Iss. 15, 2001-01 ,pp. : 2177-2192

Adis International

Access to resources Recommend Favorite

Novel Biological Agents for the Treatment of Hormone-Refractory Prostate Cancer (HRPC)

By  

Current Medicinal Chemistry, Vol. 12, Iss. 3, 2005-02 ,pp. : 277-296

Bentham Science Publishers

Access to resources Recommend Favorite

Satraplatin in Hormone-Refractory Prostate Cancer and Other Tumour Types: Pharmacological Properties and Clinical Evaluation

By McKeage Mark J.  

Drugs, Vol. 67, Iss. 6, 2007-01 ,pp. : 859-869

Adis International

Access to resources Recommend Favorite

Which drug combination for hormone-refractory prostate cancer?

By Doggrell Sheila A  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 4, 2005-04 ,pp. : 667-670

Informa Healthcare

Access to resources Recommend Favorite